Genetic Studies in Familial Dementia

Dementia Clinical Trial

Official title:

Genetic Studies in Familial Dementia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04680013
• Other study ID #: 20070307
• Secondary ID: RF1AG054080RF1AG
• Status: Recruiting
• Start date: June 1, 2007
• Est. completion date: November 1, 2025

Study information

• Verified date: December 2023
• Source: University of Miami
• Contact: Michael Prough
• Phone: 877-686-6444
• Email: AD-HIHG[@]miami.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to identify genetic factors that contribute to or cause dementia (loss of memory) and related disorders across all ages and ethnic groups. This includes a number of neurological diseases such as early and late-onset Alzheimer disease, mild cognitive impairment, and other dementias.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20000
• Est. completion date: November 1, 2025
• Est. primary completion date: November 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years and older

2. Patients diagnosed with dementia, their family members and unrelated healthy controls without dementia.

Exclusion Criteria:

1. Individuals with competing diagnosis such as: Amyotrophic lateral sclerosis, Frontotemporal lobar degeneration, Multiple system atrophy, Corticobasal degeneration, Progressive Supranuclear Palsy, Huntington's disease, traumatic brain injury, drug or alcohol abuse, or schizophrenia, etc. (unless family members of a dementia affected individual).

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer Disease, Early Onset
• Alzheimer Disease, Late Onset
• Cognitive Dysfunction
• Dementia
• Dementia of Alzheimer Type
• Mild Cognitive Impairment

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (5)

Lead Sponsor	Collaborator
University of Miami	Case Western Reserve University, Columbia University, National Institute on Aging (NIA), Wake Forest University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between genetic factors and Alzheimer disease, dementia, and related phenotypes.	Genetic factors will be measured through genome-wide genotyping arrays and/or whole-genome sequencing, and then correlated with Alzheimer disease and related phenotypes, such as cognitive impairment, functional impairment, and relevant biomarkers.; .	5 years

External Links

•   NIA Genomics of Alzheimer Disease Storage site
•   NIAGADS data distribution agreement
•   NIH/NIA Alzheimer disease genomics data sharing plan